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Abstract
Background: Functional biomarkers able to identify multiple sclerosis (MS) patients at high risk of fast disability
progression are lacking. The aim of this study was to evaluate the ability of multimodal (upper and lower limbs
motor, visual, lower limbs somatosensory) evoked potentials (EP) to monitor disease course and identify patients
exposed to unfavourable evolution.
Methods: One hundred MS patients were assessed with visual, somatosensory and motor EP and rated on the
Expanded Disability Status Scale (EDSS) at baseline (T0) and about 6 years later (T1). The Spearman correlation (rS)
was used to evaluate the relationship between conventional EP scores and clinical findings. Multiple (logistic)
regression analysis estimated the predictive value of baseline electrophysiological data for three clinical outcomes:
EDSS, annual EDSS progression, and the risk of EDSS worsening.
Results: In contrast to longitudinal correlations, cross-sectional correlations between the different EP scores and
EDSS were all significant (0.33 ≤ rS < 0.67, p < 0.001). Baseline global EP score and EDSS were highly significant
predictors (p < 0.0001) of EDSS progression 6 years later. The baseline global EP score was found to be an
independent predictor of the EDSS annual progression rate (p < 0.001), and of the risk of disability progression over
time (p < 0.005). Based on a ROC curve determination, we defined a Global EP Score cut off point (17/30) to identify
patients at high risk of disability progression illustrated by a positive predictive value of 70 %.
Conclusion: This study provides a proof of the concept that electrophysiology could be added to MRI and used as
another complementary prognostic tool in MS patients.
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Background
Evoked potentials (EP) provide quantitative functional
measures in well-defined pathways of the central ner-
vous system (CNS). In multiple sclerosis (MS), the use
of EP to diagnose the disease or assess its biological ac-
tivity has been limited, mainly because of the high sensi-
tivity of magnetic resonance imaging (MRI), especially at
the brain level [1]. There are situations though where
electrophysiological data can provide useful diagnostic
information. For instance, visual EP can demonstrate
lesional spatial dissemination [2, 3]. During the course
of MS, EP can be used to confirm unclear relapses in pa-
tients expressing vague or transitory symptoms [4]. EP
have also been used in some clinical trials targeted on
relapse anti-inflammatory treatments [5], immunomodu-
latory disease modifying drugs [6–8] and symptomatic
medications designed to facilitate the central nervous
conductions [9, 10].
Overall, EP were more sensitive than clinical metrics
to demonstrate drug efficacy [5, 6], anticipate clinical
changes [6], and help predicting good response in spe-
cific situations [9, 10].
If conventional MRI (T1, T2 and T1 + Gadolinium)
and clinical evaluation can be regarded as the standard
approach for diagnosing MS and monitoring its
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biological activity, they usually demonstrate a weak asso-
ciation known as the functional-anatomical paradox
[11–13]. By contrast, EP can evaluate long eloquent
pathways well correlated to the functional involvement
[14]. EP latency and amplitude abnormalities evaluate
the pathological conduction characteristics. Latency pro-
longation is due to demyelination, while conduction
block or axonal loss lead to reduced amplitude [15]. In
previous studies, cross-sectional correlations with EDSS
were generally good, ranging from 0.3 to 0.6 [11, 16–22].
By contrast, longitudinal correlations were weaker
[11, 17, 20, 23], which may be attributed to lower EP
reproducibility [4, 24], to a level-off effect of EP mea-
sures in patients with more advanced disease [14],
but also to a lack of responsiveness of clinical scales
[25, 26]. The weak longitudinal association is bal-
anced by the potential ability of EP to anticipate a
clinical deterioration, which could be useful for the
prognosis of the disease course [7, 16, 17, 27], espe-
cially in the era of early treatment procedure for pa-
tients with a poor prognosis. Yet, the prognostic role
of EP is not fully admitted and further studies are
needed to address this issue [28]. Therefore, the
present work aimed to evaluate the ability of multi-
modal EP, summarized by a conventional score, to




We performed a retrospective analysis of the local database
of 100 MS patients followed in our academic clinical centre
between 2001 and 2014. The selection was based on a con-
venience sampling procedure. The inclusion criteria were:
(1) a definite diagnosis of MS based on the 2001 and 2005
McDonald criteria [29, 30]; (2) a clinical follow-up of at
least 3 years, including a disability rating using the
Expanded Disability Status Scale (EDSS) obtained at base-
line (T0) and at the end of the follow-up period (T1) [31];
(3) a multimodal EP examination at T0, i.e. motor evoked
potentials from lower and upper limbs (MEP), visual
evoked potentials (VEP), and somatosensory evoked poten-
tials from lower limbs (SEP); (4) a clinically stable phase at
the time of each evaluation ensured by a 3-month period
between the previous relapse and the evaluation.
For 76 of the 100 MS patients, a second electrophysio-
logical examination was available at the end of the
follow-up period (T1) enabling a longitudinal analysis of
multimodal EP data. The study was approved by the
Local Ethics Committee (University Hospital of Liege)
and has been performed in accordance with the ICH
(International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use)
guidelines.
Evoked potentials
All electrophysiological examinations were performed by
the same investigator (XG) using the same recording sys-
tem (Keypoint, Alpine Biomed, France); clinical evalua-
tions were conducted by a non-blinded investigator (DD).
Motor Evoked Potentials (MEP) were recorded bilat-
erally from the first dorsal interosseous (FDI) in the
upper limbs and from the tibialis anterior (TA) in the
lower limbs. Each measurement started by recording the
compound muscle action potential (CMAP) elicited by a
supramaximal electrical stimulation of the ulnar nerve at
the wrist and common peroneal nerve at the knee. Then,
three transcranial magnetic stimulations (TMS) were de-
livered to the hand and leg areas of the motor cortex, re-
spectively on Cz and Fz, with a Magstim 200 device
(The Magstim Company Ltd., Whitland, UK) using a cir-
cular coil (maximal output 2.2 T). For each limb, the
shortest latency and highest amplitude event out of the
3 waves were selected for analysis. A peripheral mag-
netic stimulation was applied over the C8 and L5 nerve
root for the upper limbs and lower limbs, respectively,
to derive the central motor conduction time (CMCT).
The CMCT was obtained by subtracting the peripheral
conduction time obtained by magnetic stimulation of
the cervical and lumbar spinal roots from the cortical
MEP latency. The following MEP parameters were con-
sidered in the study: peripheral, radicular and cortical la-
tencies; CMCT; absolute baseline-to-peak amplitude
from the peripheral and cortical stimulations; amplitude
ratio (AR) expressed as the MEPampl/CMAPampl ratio;
duration of the cortical stimulation induced response
measured from the onset of the initial negative deflec-
tion to the latest positive deflection.
Visual evoked potentials (VEP) were recorded using
EEG cup electrode Ag-AgCl electrodes. The active elec-
trode was placed at Oz and the reference at Fz, based on
the 10–20 international EEG system. Monocular visual
stimulation was performed with a pattern-reversal check
board screen. The size of the squares was adjusted to sub-
tend a 15-min visual arc with an individual square. The
two parameters used for the analysis were latency of the
P100 component and N75-P100 amplitude difference.
Somatosensory evoked potentials (SEP) of the lower
extremities were obtained through posterior tibial nerve
electrical stimulation at the ankle. The afferent volley
was recorded at 3 levels by active electrodes located at
the popliteal fossa, over the intervertebral space D12-L1
and 2 cm posterior to Cz. The reference electrodes were
placed, respectively, on the lateral side of the thigh, over
the intervertebral space L5-S1 and at Fz. The parameters
studied were the latencies of the main peripheral (N9),
spinal (N21) and cortical (P40) components along with
P40-N21 difference (central sensitive conduction time)
and P40 amplitude (baseline-to-peak).
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Analysis and rating of EP data
We developed from EP data a conventional ordinal score
(EP score) modified from Jung et al. [16]. Specifically, for
the sensory EP, both latency and amplitude abnormal-
ities were included in the score. For MEP, the duration
of the cortex stimulation induced response was added to
these parameters to account for the temporal dispersion
of the corticospinal discharges. Absolute or body side
difference values above 2 standard deviations (SD) from
our local normative data were considered pathological.
For each modality and body side, the score was derived
from a 6-point graded ordinal scale summarized in Table 1.
A result in the normal range but with a pathological body
side difference received a score of 1 (for latency) and 2
(for amplitude). This score was assigned to the worst body
side. In case of absolute latency above the normal limit,
we attributed a score of 2, 3 or 4, according to the delay.
The worst and maximum score of the scale (5) was attri-
buted to an evoked response either absent or with ampli-
tude below the normal range. Hence, the EP score for
each side and each modality (UL MEP, LL MEP, LL SEP,
VEP) ranged from 0 to 5. To give equal weight to each
modality in the global EP score (MEP + SEP +VEP), we
divided the MEP score by 2 since it was derived from the
4 limbs (UL MEP + LL MEP). Thus, the overall worst
score of the scale was 30.
Statistical analysis
Results were expressed as mean and SD for quantitative
data and as frequencies (number and percent) for
categorical findings. The associations between EP scores
and clinical data were assessed by the Spearman cor-
relation coefficient (rs). Mean values between groups
(e.g. relapsing–remitting vs. progressive patients) were
compared by analysis of variance (ANOVA) and pro-
portions by the chi-square or Fisher exact test. Score
changes between T0 and T1 were assessed by the paired
Student t-test.
Multivariate methods were used to assess the 6-year
predictive value of demographic (age, size, weight, sex,
laterality), clinical (relapsing-remitting or progressive
phenotype, disease duration, follow-up duration, disease-
modifying therapy between T0 and T1) and baseline
electrophysiological (global EP score) data for three
main clinical outcomes: the EDSS score (model 1), the
annual EDSS progression score (model 2), and the EDSS
worsening (yes/no). EDSS worsening was defined as a 1-
point increase from T0 to T1 given a baseline EDSS <5.5
or an increase of 0.5 point given a baseline EDSS ≥ 5.5
[17] (model 3). The EDSS progression score per year
was obtained by the absolute EDSS progression score di-
vided by the follow-up duration in years. Multiple re-
gression was used for models 1 and 2 and logistic
regression for model 3. The quality of the fit was mea-
sured by the coefficient of determination (R2) for models
1 and 2 and by the area under the curve (AUC) for
model 3. Results were expressed in terms of regression
coefficients with their standard error (SE). Odds Ratios
(OR) and associated 95 % confidence intervals (95 % CI)
were added for the logistic model. Observed and pre-
dicted probabilities of worsening were cross-classified to
further enhance the prognostic ability of baseline EP
data. Finally, the receiver operating characteristic (ROC)
curve method was used to determine an optimal cut-off
value on the total EP scale to discern patients with poor
and favourable prognosis. Results were considered sig-
nificant at the 5 % critical level (p < 0.05). All statistical
calculations and graphs were performed with SAS (ver-
sion 9.4 for Windows) and the R software (version
3.0.3).
Results
Clinical and electrophysiological data are summarized in
Table 2. At baseline, 90 patients were in a relapsing-
remitting (RR) course, 9 patients in a secondary progres-
sive (SP) course and one patient in a primary progressive
(PP) course. The mean age was 39 years (SD 10) and the
disease duration 9.1 years (SD 8.0). EDSS averaged 3.0
(SD 1.2) and the mean global EP score was 12.1 (SD
7.6). When comparing RR and P phenotypes, significant
differences were observed for all clinical and electro-
physiological parameters (except VEP) even after adjust-
ment for disease duration.
After a median follow-up period of 6.3 years, the dete-
riorations of EDSS (+0.6; SD 1.1) and of the global EP
score (+2.7; SD 3.9) were highly significant (p < 0.0001),
as were those of lower limbs MEP and SEP. By contrast,
the visual functional system progression, although sig-
nificant (p < 0.05), was less marked, while the sensory
functional system did not evidence any change. In classi-
fying clinical and EP data with respect to their relative
progression over time, we found that the global and LL
Table 1 Description of the 6-point graded EP ordinal scale
EP results (MEP, SEP, VEP) Score
Normal (ampl and lat) 0
Pathological body side difference lat 1
Pathological body side difference ampl or pathological
lat but < P33.3
2
P33.3 < lat < P66.7 or increased duration of the cortical
stimulation induced response (MEP)
3
P66.7 < lat 4
Pathological ampl and normal duration of the cortical
stimulation induced response (MEP)
5
EP evoked potentials, MEP motor evoked potentials, SEP somatosensory
evoked potentials, VEP visual evoked potentials, Ampl amplitude, Lat latency,
P33.3, first tertile, derived from the MS sample presenting a pathological
latency; P66.7, second tertile, derived from the MS sample presenting a
pathological latency; MEP, motor evoked potentials
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MEP scores presented a worsening nearly twice as high
as clinical measures (Table 3).
As seen in Table 4, the cross-sectional correlations (T0
and T1) between the different EP scores and EDSS or
their related functional systems were all significant. The
best association concerned the aggregate scores: global
EP score and EDSS (rs = 0.67, p < 0.001). Longitudinally
(T0→T1), the only significant correlation was attrib-
uted to the motor function for a follow-up period longer
than 6.3 years (T0→T1).
When predicting EDSS at T1 from baseline covariates
by multiple regression analysis (model 1), only the global
EP score and EDSS at baseline turned out to be signifi-
cant after adjusting for follow-up time. None of the
other parameters (e.g. demographic parameters, phenotype,
disease duration, follow-up duration, disease-modifying
therapy) were predictive of the outcome (Table 5). The
strong correlation (R2 = 0.72) between observed and
predicted EDSS from model 1 at T1 evidenced the high
performance of the disability prediction (Fig. 1). When dis-
carding EDSS from the model 1, the global EP score still
explained more than half (R2 = 0.61) of the variance of
EDSS at T1. Now, when considering the annual progres-
sion of EDSS (model 2), the global EP score at baseline was
the only significant predictive parameter but the quality of
the model was much lower (R2 = 0,21) (Table 5).
Among the 100 MS patients at baseline, 38 evidenced
an EDSS worsening during follow-up and 89 % received
a disease-modifying therapy between T0 and T1. Logistic
regression analysis (model 3) was applied to evaluate the
probability of disability worsening based on the same
demographic, clinical and electrophysiological factors
(Table 6). When accounting for follow-up duration, only
the baseline global EP score was found to be of signifi-
cant prognostic value (OR = 1.2; 95 % CI 1.1–1.3; p =
0.0012). Interestingly, the baseline EDSS (p = 0,24) did
not impact the prediction, as for the factor therapy (bin-
ary variable) between T0 and T1 (p = 0,05). The
Table 2 Mean (SD) of clinical and electrophysiological characteristics recorded at baseline
All patients RR P RR versus P
(n = 100) (n = 90) (n = 10) p* p**
F/M ratio 62/38 59/31 3/7 0.040 0.072
Age (yrs) 39 (10) 37 (9) 53 (7) <0.0001 <0.0001
Disease duration (yrs) 9 (8) 8 (7) 19 (11) 0.0030 NA
EDSS (0.0–10.0) 3.0 (1.2) 2.8 (1.0) 5.0 (0.83) <0.0001 <0.0001
Global EP score (/30) 12.1 (7.6) 11.2 (7.4) 19.8 (5.4) 0.0006 0.011
UL MEP score (/10) 2.6 (3.0) 2.3 (2.9) 5.0 (3.3) 0.0064 0.035
LL MEP score (/10) 3.9 (3.4) 3.5 (3.3) 7.4 (2) 0.0004 0.0057
LL SEP score (/10) 4.7 (3.4) 4.4 (3.4) 7.5 (1.8) 0.0047 0.020
VEP score (/10) 4.2 (3.6) 4.0 (3.5) 6.1 (3.9) 0.079 0.35
MS multiple sclerosis, RR relapsing-remitting, P progressive, SD standard deviation, F female, M male, EDSS expanded disability status scale, EP evoked potentials,
UL upper limb, LL lower limb, MEP motor evoked potentials, SEP somatosensory evoked potentials, VEP visual evoked potentials, NA not applicable
*p-value of the comparison between relapsing and progressive courses; **p-value of the comparison between relapsing and progressive courses adjusted for
disease duration
Table 3 Clinical and EP data ranked according to their relative progression (N = 76 MS patients)
Score T0 T1 T1–T0 p* T1‐T0Max %ð Þ
LL MEP score (/10) 3.6 (3.2) 5.5 (3.6) 1.9 (2.8) <0.0001 18.8
Global EP score (/30) 11.5 (7.0) 14.2 (7.5) 2.7 (3.9) <0.0001 8.9
LL SEP score (/10) 4.3 (3.3) 5.1 (3.6) 0.75 (2.0) 0.0019 7.5
UL MEP score (/10) 2.4 (2.8) 3.2 (3.3) 0.75 (2.8) 0.021 7.5
VEP score (/10) 4.2 (3.5) 4.9 (3.5) 0.61 (2.2) 0.017 6.1
EDSS (/10) 2.9 (1.1) 3.4 (1.6) 0.58 (1.1) <0.0001 5.8
pFS (/6) 2.1 (1.1) 2.4 (1.2) 0.30 (0.91) 0.0049 5.0
vFS (/6) 0.80 (1.1) 1.1 (1.0) 0.26 (0.98) 0.023 4.4
sFS (/6) 1.8 (0.93) 1.9 (0.95) 0.013 (0.97) 0.91 0.22
MS multiple sclerosis, EP evoked potentials, UL upper limb, LL lower limb, MEP motor evoked potentials, SEP somatosensory evoked potentials, VEP visual evoked
potentials, EDSS expanded disability status scale, mFS pyramidal functional system, sFS sensory functional system, vFS visual functional system, Max maximal
theoretical value for each individual score (i.e. 30 for Global EP score, 10 for individual EP score and EDSS, 6 for functional system)
* p-value of the evolution between T0 and T1 (median follow-up = 6.3 years)
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prognostic efficacy of model 3 was high (AUC = 0.84).
When predicting EDSS worsening by the sole global EP
score at baseline, the AUC was 0.77, only slightly less
than for the full model. Further, a global EP score of 17
(over a scale of 30) was determined as the best cut-off
point at baseline to identify patients at high risk of EDSS
aggravation (Fig. 2). This cut-off yielded a sensitivity of
56.7 %, a specificity of 88.3 % with a corresponding posi-
tive predictive value (PPV) of 70.8 %.
Discussion
For the past 30 years, MS diagnosis, disease activity
monitoring, and clinical trials have been essentially
based on clinical and conventional MRI data. At the
individual follow-up level, though, there is an apparent
paradox between clinical metrics and MRI T2 lesion
load [12]. This paradox is due to a subclinical activity
before the first clinical symptoms in the early stage of
the disease [32]. Up to 50–70 % of patients with a clinic-
ally isolated syndrome (CIS) exhibit clinically silent T2-
weighted lesions [33]. After the relapsing-remitting
phase, disability progresses without any MRI focal in-
flammatory activity due to axonal loss and diffuse in-
flammatory infiltration, which is not visible through
conventional MRI [34–36].
Electrophysiology provides functional quantified data
on multimodal afferent and efferent pathways through
the brain and long spinal tracks. A standardized
Table 4 Cross-sectional (T0, T1) and longitudinal (T0→T1) correlations (Spearman correlation) between electrophysiological and
clinical data
T0 T1 T0→T1 T0→T1 (≤6,3 y) T0→T1 (>6,3 y)
(n=100) (n=76) (n=76) (n=38) (n=38)
EDSS vs UL MEP 0.47 *** 0.49 *** Δ EDSS vs Δ UL MEP 0.20 0.08 0.31
EDSS vs LL MEP 0.62 *** 0.60 *** Δ EDSS vs Δ LL MEP 0.16 −0.13 0.44 **
EDSS vs LL SEP 0.61 *** 0.54 *** Δ EDSS vs Δ LL SEP 0.11 0.05 0.19
EDSS vs VEP 0.33 *** 0.34 ** Δ EDSS vs Δ VEP 0.10 0.17 0.05
EDSS vs Global EP 0.67 *** 0.66 *** Δ EDSS vs Δ Global EP 0.18 0.07 0.28
pSF vs UL MEP 0.52 *** 0.56 *** Δ pSF vs Δ UL MEP 0.24 * 0.16 0.34 *
pSF vs LL MEP 0.56 *** 0.58 *** Δ pSF vs Δ LL MEP 0.16 −0.05 0.38 *
sSF vs LL SEP 0.53 *** 0.50 *** Δ sSF vs Δ LL SEP 0.18 0.12 0.25
vSF vs VEP 0.38 *** 0.40 *** Δ vSF vs Δ VEP 0.17 0.36 * 0.01
* p ≤ 0.05 ** p < 0.01 *** p < 0.001; 6.3 y = median follow-up in years in considered patients; EP evoked potentials, UL upper limb, LL lower limb, MEP motor
evoked potentials, SEP somatosensory evoked potentials, VEP visual evoked potentials, EDSS expanded disability status scale, mFS pyramidal functional system, sFS
somatosensory functional system; visual functional system; Δ, delta EDSS
Table 5 Prediction models of EDSS (model 1) and annual EDSS progression (model 2) from baseline data
Model 1 Model 2
EDSS EDSS progression/year
(n=100, R2=0.72) (n=100, R2=0.21)
Baseline Predictor Regression coefficient ± SE p-value Regression coefficient ± SE p-value
Intercept 2.8 ± 3.3 0.39 0.33 ± 0.59 0.58
Age (yrs) −0.0033 ± 0.014 0.81 −0.00001 ± 0.0025 0.99
Height (cm) −0.015 ± 0.021 0.48 −0.0015 ± 0.0038 0.69
Weight (kg) −0.0059 ± 0.0098 0.55 −0.0015 ± 0.0018 0.39
Sex (1= male) 0.090 ± 0.31 0.77 0.028 ± 0.056 0.62
Laterality (1=left) −0.066 ± 0.38 0.86 −0.046 ± 0.070 0.52
Phenotype (1 = SP or PP) 0.39 ± 0.46 0.40 0.010 ± 0.083 0.90
Disease duration (yrs) 0.0054 ± 0.016 0.73 0.0027 ± 0.0029 0.35
Follow-up duration (yrs) 0.036 ± 0.046 0.43 NA NA
DMT (1 = yes) 0.18 ± 0.37 0.63 0.057 ± 0.066 0.39
EDSS 0.75 ± 0.13 <0.0001 −0.035 ± 0.025 0.16
EP Score 0.082 ± 0.018 <0.0001 0.012 ± 0.0034 0.0006
EDSS expanded disability status scale; R2 multiple determination coefficient, SE standard error, SP secondary progressive, PP primary progressive, DMT disease-
modifying therapy during the follow-up, EP evoked potentials, NA not applicable. Baseline predictors with p-value < 0.05 are highlighted in bold
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procedure was developed to study highly relevant func-
tions (VEP, LL SEP and 4 limbs MEP). We advocate that
our EP battery (VEP, UL and LL MEP and LL SEP),
which takes 90–120 min depending on the patient’s
compliance, constitutes the best trade-off between time
efficiency and information relevance. As mentioned pre-
viously, to improve the EP prognostic yield, it seems
more important adding EP modalities than repeating
electrophysiological evaluations within a short period of
time [37]. In our study, a post hoc analysis designed to
investigate the individual contribution of EP modalities
showed that restricting the test battery to VEP and UL
MEP did not significantly lowered the predictive power
of our models. This observation is in line with Schlaeger
et al. who stated that, for the long term disability predic-
tion, VEP and UL MEP were the most relevant variables
[38]. However, in another study aimed to prognosticate
the future disability in a sample of primary progressive
patients, the same authors claimed that multimodal EP
(VEP, UL and LL MEP, UL and LL SEP) could be simpli-
fied to a test battery containing only UL MEP and LL
SEP without loss of information [19]. From these obser-
vations, it appears that the superiority of one EP modal-
ity over another in the prognostic field depends on the
population characteristic in terms of phenotype, disabil-
ity and disease duration at the time of the electrophysio-
logical assessment.
Latency, conduction times, and amplitude parameters
were taken into account to evaluate demyelination and
axonal loss or conduction blocks. We constructed a
composite neurophysiological score and retrospectively
applied it to 100 MS patients followed for a median dur-
ation of about 6 years. Cross-sectional correlations with
EDSS were good, in agreement with those reported in
previous studies [11, 16–22, 27, 39]. The global EP score
in the progressive form (19.8/30) was significantly higher
than in the RR form (11.2/30) regardless of disease dur-
ation, and was closely related to clinical metrics (Table 2).
This difference is mainly attributed to motor and
Fig. 1 Correlation between observed and predicted EDSS at T1 from
model 1. EDSS, Expanded Disability Status Scale
Table 6 Prediction model of EDSS worsening from baseline
data
Model 3 EDSS worsening (n=100, AUC=0.84)
Baseline Predictor Coefficient ± SE p-value OR (95 % CI)
Intercept −0.87 ± 8.4 0.92
Age (yrs) 0.0016 ± 0.035 0.97
Height (cm) −0.032 ± 0.053 0.55
Weight (kg) 0.0057 ± 0.027 0.83
Sex (1= male) 0.34 ± 0.79 0.67
Laterality (1=left) −0.34 ± 0.99 0.73
Phenotype (1 = SP or PP) 0.78 ± 1.2 0.53
Disease duration (yrs) 0.12 ± 0.048 0.01
Follow-up duration (yrs) 0.029 ± 0.12 0.82
DMT (1 = yes) 3.1 ± 1.6 0.05
EDSS −0.42 ± 0.36 0.24 0.66 (0.32–1.3)
EP Score 0.18 ± 0.054 0.0012 1.2 (1.1–1.3)
EDSS expanded disability status scale, AUC area under the ROC Curve, OR odds
Ratio, CI confidence interval, EP evoked potentials, EDSS worsening, 1-point
increase from T0 to T1 given a baseline EDSS <5.5 or an increase of 0.5 point
given a baseline EDSS ≥ 5.5; DMT, disease-modifying therapy during the
follow-up. Baseline predictors with p-value < 0.01 are highlighted in bold
Fig. 2 ROC curve of baseline global EP score with respect to EDSS
worsening. Area under the ROC curve (AUC = 0.77) and best cut-off
point (Global EP score = 17/30) with a sensitivity of 56.7 % and a
specificity of 88.3 %. EDSS worsening (Yes/No) was defined as a
1-point increase from T0 to T1 given a baseline EDSS <5.5 or an
increase of 0.5 point given a baseline EDSS ≥5.5
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somatosensory EP, suggesting a higher implication of
spinal cord dysfunction in the progressive phenotype
[40]. The lower correlation between VEP and EDSS also
confirms that EDSS overweighs ambulation and spinal
cord metrics and relatively underweighs more advanced
measures of visual disability like change in low contrast
vision, colour vision or visual field. We confirmed the
markedly weaker longitudinal correlations already no-
ticed by other authors [11, 17, 20, 23]. The relative lon-
gitudinal progression rate of clinical data illustrates the
low EDSS sensitivity to change with a nearly twice
higher deterioration of the global EP score and LL MEP
score compared to EDSS and the functional systems
(Table 3). The weaker correlation in the subgroup with
the shorter follow-up is probably an additional argument
for the lower EDSS sensitivity. The EDSS scale needs a
sufficient amount of time to measure functional changes
detected at an earlier stage by electrophysiology. On the
other hand, high EP score level or progression, with long
track dysfunction, is not necessarily associated with a
clinical deterioration due to plasticity or adaptation but
certainly indicates a depletion of functional reserve [41].
This ability of EP to anticipate a clinical deterioration
constitutes the most salient result of our study. In the
past, models with EP alone [37, 39] or integrated in
multivariate approaches [19, 20, 38, 42] were used to
forecast disability and disability progression for relatively
homogenous samples [19, 22, 37, 43]. In this context, we
performed a multivariate analysis to define a model able
to predict the EDSS score at 6 years. Predicted and ob-
served EDSS were highly correlated in agreement with
published data obtained in smaller groups and in specific
conditions [19, 37]. The statistical analysis showed that
the initial global EP score and EDSS explain a significant
part of the variance of the EDSS, 6 years later. Further-
more, the baseline global EP score was the unique sig-
nificant factor able to predict the EDSS annual
progression rate (p < 0.001) and the risk of EDSS wors-
ening after a median follow up period of 6.3 years (p <
0.005). Our study also provides an EP score cut-off limit
of 17, on a scale ranging from 0 to 30, which is poten-
tially useful at the individual level as it suggests that a
patient with a Global EP score higher than 17/30 ex-
hibits a risk of clinical worsening of around 70 %. To
some extent, this observation provides a proof of the
concept that electrophysiology could be used as part of a
prognostic armamentarium in MS.
The present study was limited by the retrospective de-
sign and by the heterogeneity of the follow-up duration
between subjects. Nevertheless, the multivariate analysis
showed that this variability didn’t impact outcome pre-
diction. While the therapeutic factor did not significantly
impact the prognosticating potential of our EP score, as
previously argued by Schlaeger on a smaller sample size
[42], it would be valuable, in the era of highly active
therapies, to design a prospective study focused on the
prognostic interplay between EP and immunomodula-
tory drugs. Further studies are however needed to imple-
ment spinal and cerebral MRI metrics as well as to
confirm the validity of our models, based on the same
EP procedure but with other datasets. It could be useful,
and not redundant, to integrate clinical, neurophysio-
logical functional data and anatomical information to
define a multivariate prognostic index.
Furthermore, EP amplitude measures can indirectly re-
flect central axonopathy, which is highly correlated with
irreversible disability. Motor triple stimulation technique
can precise and quantify corticospinal conduction failure
and should be more largely implemented in the electro-
physiological evaluation [44].
Conclusion
In conclusion, multimodal EP, summarized in an ordinal
score, seem to be well suited as a biomarker of the MS
disease course given the high correlations observed with
EDSS at any time point. Using a multivariate approach
we proposed models for EDSS prediction and for the
risk of clinical aggravation at a second follow-up time
point. Based on ROC curve analysis we were able to de-
fine an EP score cut-off point which is associated with a
high risk of disability progression. At the individual clin-
ical level, this finding could be a relevant and independ-
ent argument for early highly active therapy. It could
also support the process of patient selection in the scien-
tific settings.
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